D-103

Analytical Method Validation and Verification

Section D — Laboratory Operations and Specifications Revision 8 16 pages

Original Document

Scanned document (image-only PDF)

Extracted Text

Searchable text extracted from PDF

1.0 Purpose 
 
 The purpose of this procedure is to define the process for validation and verification of analytical
 
 test methods. Specific requirements for accredited tests for ISO 17025 are also included in this
 procedure. 
 
 2.0 Scope 
 
 2.1 This procedure applies to the validation and verification of analytical test methods
 
 intended for use in the QC laboratory at Ion Labs. This procedure is applicable to the
 
 validation of non-standard methods and lab-developed methods offered to customers as
 an accredited test or a part of an accredited test in accordance with [ISO 17025:2017. If
 
 a published, standard method is utilized beyond its intended scope, then this procedure is
 applicable as validation of the method is required. 
 
 The Test methods listed below will be validated in accordance with ISO 17025:2017
 
 requirements: 
 
 Ion Labs ISO 17025:2017 Accredited Test Methods 
 D-720 Caffeine Determination using HPLC with UV/VIS Detection 
 D-729 Determination of Tributyrin by GC-FID 
 D-776 Cannabinoid Determination and Identification by HPLC 
 
 D-778 Limit of Citrinin by LC-MS 
 D-780 Determination of Quercetin by HPLC using UV-VIS Spectroscopy
 D-715 Microbial Testing Using 3M Petrifilm 
 D-715.0 Microbial Limit Test Using Agar 
 
 2.2 This procedure is not applicable to discovery activities where tests are being designed.
 
 2.3 This procedure does not apply to heavy metal and mineral validations.
 
 2.4 The parameters listed in this procedure may not apply to the validation of microbial limit
 
 tests. 
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 8 Page 2 of 16 
 Analytical Method Validation and Verification D-103 
 
 3.0 Responsibility 
 
 an It is the responsibility of QC Laboratory analysts and/or AD personnel to execute
 validation and verification protocols. 
 
 a2 QC Laboratory Management and/or AD personnel are responsible for writing validation
 
 and verification protocols, ensuring analysts properly execute protocols, and preparing,
 reviewing, and approving data summaries and reports. 
 
 3.3 It is the responsibility of QC Laboratory Management and/or AD personnel to keep this
 
 procedure current with the latest lon Labs Practices. 
 
 4.0 Definitions 
 
 4.1 UV/VIS — Ultraviolet and Visible Light Spectrums 
 
 4.2 ICP/MS — Inductively Coupled Plasma / Mass Spectrometry 
 
 4.3 AOAC - Association of Analytical Communities 
 
 4.4 USP — United States Pharmacopeia 
 
 4.5 EP — European Pharmacopeia 
 
 4.6 QC — Quality Control 
 4.7 AD — Analytical Development 
 
 4.8 R&D — Research and Development 
 
 4.9 SOP — Standard Operating Procedure 
 
 4.10 DL — Detection Limit 
 
 4.11 QL — Quantitation Limit 
 
 4.12 Customer — The Ion Labs Inc. Laboratory is employed by Ion Labs and the customer
 described in this procedure is a designee of Ion Labs Inc 
 
 5.0 References 
 
 5.1 Analytical Procedures and Methods Validation for Drugs and Biologics, US Department
 
 of Health and Human Services, Food and Drug Administration, July 2015
 
 ee USP <1225> Validation of Compendial Procedures 
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 Page 3 of 16 
 Analytical Method Validation and Verification D-103 8 
 
 a3 USP <1226> Verification of Compendial Procedures 
 
 5.4 ICH Q2(R1) Validation of Analytical Procedures: Text and Methodology
 5.5 USP <1092> The Dissolution Procedure: Development and Validation 
 
 5.6 D-777, SOP, Elemental Analysis by ICP-MS 
 
 5.7 D-715, SOP, Microbial Testing using 3M Petrifilm 
 
 5.8 D-715.0, SOP, Microbial Limit Test Using Agar 
 
 6.0 Method Development and Documentation 
 
 6.1 Test methods which refer to or meet a published/accepted standard will be developed to
 
 refer to the most current revision of that standard. The method will identify the revision
 used. Test methods will be reviewed and updated as the referenced standard changes.
 
 6.1.1 Ifpublished/accepted methods do not describe the specific equipment or facilities
 
 used or not what is available in the laboratory, or if the method does not contain
 full details to allow the method to be completed, a supplemental method document
 
 including the above-described requirements will be generated to allow Lab
 
 personnel to complete the method. 
 6.1.2 All methods, procedures and supporting documentation, such as instructions,
 
 standards, manuals and reference data relevant to the laboratory activities, shall
 
 be kept up to date and shall be made readily available to personnel.
 
 6.1.3. The laboratory shall ensure that it uses the latest valid version of a method unless
 it is not appropriate or possible to do so. When necessary, the application of the
 
 method shall be supplemented with additional details to ensure consistent
 application. 
 
 6.2 Deviations from methods for all ISO 17025 accredited laboratory activities are authorized
 
 only if the deviation has been documented, technically justified, authorized, and accepted
 by the customer. Records of the deviation authorization and customer acceptance are
 
 retained. 
 
 6.3 Every standard ISO 17025 accredited test which is offered to customers will be
 documented in a test method. The method may refer to other existing documentation and
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 Page 4 of 16 
 Analytical Method Validation and Verification D-103 8 
 
 instructions e.g., test item preparation specifications, sampling procedures, identification,
 handling and preservation procedures and facility, maintenance, and cleaning procedures,
 
 as necessary. 
 
 7.0 Procedural Principles and Methodology 
 
 7.1 Validation and verification are different processes. Typically, non-standard (e.g.,
 
 developed in-house) methods, standard methods used outside their intended use, or
 amplified or modified standard methods are validated while compendial or standard
 
 (official) test methods are verified. If non-standard methods are appropriate to a situation
 within the accredited scope of test for ISO 17025:2017, including lab-developed methods,
 
 standard methods used outside of their intended scope and modifications, extensions etc.,
 the non-standard method will be developed and documented in accordance with this
 
 procedure and agreed to by the customer. These non-standard methods will also be fully
 
 validated before use. The degree of planning, development, documentation, and
 validation is as extensive as necessary to meet the needs of the given application or field
 
 of application. 
 
 7.2 Methods intended for use only in investigational testing (not for product or raw material
 release) do not require validation or verification. 
 
 Validation of an analytical procedure is the process by which it is established, by
7.3 laboratory studies, that the performance characteristics of the procedure meet the

 requirements for the intended analytical application. Validation for ISO 17025 accredited
 
 tests (listed above in section 2.1) will also take the factors that contribute to the total
 
 uncertainty of all measurements into account when developing methods and procedures.
 
7.4 Verification of a compendial or official test method is the assessment of whether the

 procedure can be used for its intended purpose, under the actual conditions of use.
 7.4.1. A compendial or official test method that falls under the method verification
 
 process meets one of the following attributes. 
 7.4.1.1. The method is listed in the current USP or in another pharmacopeia such
 
 as the EP. 
 
 741.2 The method is listed in a document such as the Official Methods of
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev fein an eae 
 Analytical Method Validation and Verification D-103 8 poueaes 
 
 Analysis of AOAC International or the Food Chemicals Codex.
 
 7.4.1.3 The method is validated and the validation documented (e.g. vendor’s
 test method or published journal article). 
 
 7.4.1.4 Only modifications to the stated procedure listed in USP <621>
 
 Chromatography (System Suitability section) may be made for
 verifications. If modifications not listed in USP <621> are made,
 
 validation must be performed on the method. 
 
 7.4.1.5 Verification is not required for common compendial test procedures that
 are routinely performed in a laboratory such as: 
 
 7.4.1.5.1 Loss on drying. 
 
 7.4.1.5.2 Residue on ignition. 
 
 7.4.1.5.3 Wet chemical procedures such as acid value. 
 
 7.4.1.5.4 Instrumental methods such as pH or Karl Fischer.
 
 7.4.1.6 Verification of compendial or official test methods intended for the
 analysis of dietary supplements is optional (EXCEPTION: an ISO
 
 17025 accredited test listed above in Section 2.1- all ISO 17025
 accredited tests using compendial or official test methods must be
 
 verified); however, verification is prudent for highly complex analytical
 
 determinations. 
 
 7.4.1.6.1 Verification is required for compendial or official test
 methods that will be incorporated into an SOP. 
 
 7.5 This procedure outlines the typical elements that may be used to validate or verify a test
 
 method. The parameters and acceptance criteria listed in this document are directly
 applicable to chromatographic test methods; however, the concepts may be applied to
 
 different test methods that may require alternate schemes. 
 
 7.6 Method validation and verification are protocol driven activities. The validation or
 verification protocol should include, at a minimum, the following information:
 
 7.6.1 A brief description of the method including the source, purpose, and general
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 Analytical Method Validation and Verification D-103 8 Page 6 of 16 
 
 operating principle. 
 
 7.6.2 The specific analytical attributes to be evaluated. 
 7.6.2.1 Attributes to be evaluated should be chosen based on the guidance given
 
 in Sections 8.0 (for validations) and 9.0 (for verifications).
 
 7.6.2.2. More or fewer analytical attributes may be required depending on the
 
 intended purpose and complexity of the procedure. 
 
 7.6.3 The acceptance criteria to be met. 
 7.6.3.1 Acceptance criteria should be established based on the guidelines given
 
 in Section 10.0. 
 
 7.7 The results generated during method validation, method verification, or method
 development shall not be used for finished product release. To ensure this, the following
 
 guidelines will be adhered to: 
 
 7.7.1. Sequences generated during method validation, verification or development
 shall not be stored in the same project folder as those generated for finished
 
 product release. 
 
 7.7.2 Sequence names and sample names for sequences generated during method
 validation, verification or development shall not include a batch number. The
 
 product name, formula number, or test identifier (e.g. PREC-1, PREC-2, PREC-
 
 3) should be used instead. 
 
 7.7.3. Finished product samples shall not be used for method validation, method
 verification, or method development. Samples that are acceptable to use for
 these activities include: 
 
 7.7.3.1. A sample that has been generated in the laboratory according to the
 product formulation and is not intended for commercial sale.
 7.7.3.2. A sample that was obtained from a production batch immediately
 after blending but before further processing (e.g. encapsulation,
 
 compression, packaging). 
 7.7.3.3 A finished product sample that has been adulterated by the addition
 of an unknown quantity of excipient. The amount of adulterant added
 
 shall not be quantified, but should be limited to no more than % of the
 total sample amount by visual inspection. Acceptable adulterants
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 Page 7 of 16 
 Analytical Method Validation and Verification D-103 8 
 
 include: 
 7.7.3.3.1 Microcrystalline cellulose for tablets, capsules, powders,
 and chewable tablets. 
 
 7.7.3.3.2 Sucrose for chewable gels (gummies). 
 7.7.3.3.3. Glycerin for glycerin based liquids or liquid capsules.
 
 7.7.3.3.4 Olive oil for oil based liquids or liquid capsules.
 
 7.7.3.3.5 Other adulterants may be used with scientific justification.
 7.8 Upon successful completion of a validation or verification, a technical report will be
 
 generated documenting the results. 
 
 7.9 Upon successful completion of a validation or verification, all details of the method as
 executed should be compiled into a Standard Operating Procedure for routine use.
 
 8.0 Method Validations 
 
 8.1 USP <1225> Validation of Compendial Procedures defines the following categories of
 
 analytical test methods. These categories may be extended to apply to dietary
 supplements, functional foods, cosmetics, and companion animal products.
 
 8.1.1 Category I— Analytical procedures for quantitation of major components of bulk
 
 drug substances or active ingredients (including preservatives) in finished
 pharmaceutical products. 
 
 8.1.2 Category II — Analytical procedures for determination of impurities in bulk drug
 
 substances or degradation compounds in finished pharmaceutical products. These
 procedures include quantitative and limit tests. 
 
 8.1.3 Category III — Analytical procedures for the determination of performance
 
 characteristics (e.g. dissolution). Validation or verification of a dissolution
 procedure is beyond the scope of this document. Refer to USP <1092> The
 
 Dissolution Procedure for further guidance on validation of dissolution
 
 procedures. 
 
 8.1.4 Category IV — Identification tests. 
 8.2 For each category, different analytical information is needed. The performance
 
 characteristics required for each category of analytical procedure are listed in Table 1.
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 D-103 8 Page 8 of 16 
 Analytical Method Validation and Verification 
 
 Table 1: Performance Characteristics Required for each Method Category 
 
 jokes Category I se Category | “*fesory 
 Characteristic Quantitative | Limit Test lil IV 
 
 Accuracy Yes Yes * * No 
 
 Precision Yes Yes No Yes No 
 
 Specificity Yes Yes Yes : Yes 
 Detection Limit No No Yes * No 
 
 Quantitation Limit No Yes No * No 
 Linearity Yes Yes No * No 
 
 Range Yes Yes * * No 
 
 * May be required, depending on the nature of the specific test 
 
 8.3 Robustness is typically evaluated during the method development stage. If the method is
 
 found to be susceptible to variation in its parameters, these parameters should be
 adequately controlled and a precautionary statement included in the method
 
 documentation. 
 
 8.4 Refer to Section 10.0 for guidance regarding analytical approach and establishing
 acceptance criteria. 
 
 8.5 Analytical methods for dietary supplements, cosmetics, and functional foods are
 
 validated or verified for individual analytes as opposed to individual products.
 
 8.6 Analytical methods for drug products are validated for each individual product. For
 application of a previously validated or verified method to a finished product that has not
 
 been analyzed using the method before, Specificity, Accuracy, and Precision should be
 performed for the new product, a report documenting the results should be generated, and
 
 the procedure should be updated to refer to the report, and the scope of the procedure
 
 should be updated to include the formula number of the product. 
 
 9.0 Method Verification 
 
 9.1 Verification requirements should be based on the complexity of the procedure and the
 material to which the procedure is applied. Although complete revalidation of a
 
 compendial method is not required to verify the suitability of a procedure under actual
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 Analytical Method Validation and Verification D-103 8 Page 7 of 16 
 
 conditions of use, some of the analytical performance characteristics listed in Table 1
 may be used for the verification process. Only those characteristics that are considered
 
 appropriate for the verification of the procedure need to be evaluated.
 
 9.2. Assessment of the laboratory personnel, facilities, equipment, instrumentation, and
 item(s) under test should be performed. 
 
 9.2.1 Laboratory personnel should have the appropriate experience, knowledge, and
 
 training to understand and perform the compendial procedures.
 
 9.2.2 Facilities, equipment, and instrumentation should be capable of performing the
 compendial method as intended. 
 
 9.2.3 The item(s) under test should be assessed for complexity of the “formulation” as
 
 compared to the intended use of the compendial procedure. 
 
 9.3. Robustness is generally not evaluated during method verification. 
 
 9.4 For method verification, the System Suitability criteria listed in the compendial method
 should be used without alteration. 
 
 10.0 Acceptance Criteria for Validations and Verifications 
 
 10.1. The criteria outlined in this section are general guidelines that are appropriate for the
 
 majority of validations and verifications performed at Ion Labs. Alternate criteria may be
 established if they are scientifically justified, and results meeting the requirements
 
 provide confidence that the procedure is suitable for its intended use.
 
 10.2 Accuracy expresses the closeness of agreement between the true value and the observed
 
 value. 
 10.2.1 Category I methods are typically evaluated for Accuracy across the range of the
 
 analytical procedure. For example, a placebo may be spiked at 80%, 100%, and
 
 120% of the nominal concentration. 
 10.2.2 Category II methods are typically evaluated for Accuracy at the limit level. The
 
 sample may be spiked with target analyte to approximate the limit level.
 
 10.2.3 A number of approaches for evaluating Accuracy are listed below. The most
 appropriate strategy for the method category and test sample should be chosen.
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 Analytical Method Validation and Verification | D-103 | 8 | Fase 10016 
 
 10.2.3.1 Apply the procedure to synthetic mixtures of the product (placebo) to
 which known quantities of the target analyte have been added. Calculate
 
 the recovery of spiked target analyte. 
 
 10.2.3.2 Apply the procedure to a test sample with known quantity of the target
 analyte (reference substance). Evaluate the difference between the
 
 theoretical and observed values. 
 
 10.2.3.3 Apply the procedure to a test sample and compare the results to that of
 a second, well-characterized method. 
 
 10.2.3.4 Amend a sample with the target analyte. Apply the procedure to the test
 
 sample and the spiked test sample. Calculate the recovery of the spiked
 analyte. 
 
 10.2.3.5 Infer accuracy based on the successful demonstration of Specificity,
 
 Precision, and Linearity. 
 
 10.2.4 The degree of replication required is dependent upon the sample type.
 
 10.2.4.1 For dietary supplements, functional foods, cosmetics, and companion
 animal products, a single replicate, or one replicate at each concentration
 
 level may be sufficient. 
 
 10.2.4.2 For drug products, triplicate sample preparations at each of three
 concentration levels is appropriate for Category I methods while six
 
 replicates at the limit level is appropriate for Category II methods.
 
 10.2.5 Acceptance criteria should be chosen to ensure that the method performs as
 intended based on the method category and sample type. For strategies using
 
 replicate sample preparations, only the mean need be evaluated for acceptance
 
 since precision is assessed independently of accuracy. 
 10.2.5.1 For dietary supplements, functional foods, cosmetics, and companion
 
 animal products: within 5% of the expected value is usually appropriate
 for Category I methods, while within 10% of the expected value is
 
 acceptable for Category II methods. 
 
 10.2.5.2 For drug products: within 2% of the expected value is usually
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 Analytical Method Validation and Verification D-103 g. | meee Dbott6 
 
 appropriate for Category I methods, while within 10% of the expected
 value is acceptable for Category II methods. 
 
 10.3. Precision expresses the closeness of agreement between a series of measurements
 
 obtained from multiple sampling of the same homogeneous sample under the prescribed
 conditions. 
 
 10.3.1 Precision is evaluated by analyzing replicate sample preparations and calculating
 
 the %RSD of the results. 
 
 10.3.2 For Category II methods, the sample may be amended with target analyte to
 approximate the limit level if sufficient analyte is not already present.
 
 10.3.3 The degree of replication is dependent upon the sample type.
 
 10.3.3.1 For dietary supplements, functional foods, cosmetics, and companion
 
 animal products, the sample should be prepared in_ triplicate.
 Alternately, for Category I procedures, the sample may be prepared at
 
 three concentrations spanning the range of the method. 
 
 10.3.3.2 For drug products, six replicate sample preparations is appropriate. For
 Category I methods, triplicate sample preparations at each of three
 
 concentration levels spanning the range of the method is also acceptable.
 
 10.3.4 Acceptance criteria should be chosen to ensure that the method performs as
 intended based on the method category and sample type. 
 
 10.3.4.1 For dietary supplements, functional foods, cosmetics, and companion
 
 animal products, less than 5.0% RSD for Category I and III methods, or
 less than 10.0% RSD for Category II methods is acceptable.
 
 10.3.4.2 For drug products, less than 2.0% RSD for Category I methods, or less
 
 than 10.0% RSD for Category II methods is appropriate. 
 
 10.4 Specificity is the ability to assess unequivocally the analyte in the presence of
 components which may be expected to be present such as impurities, degradants, or
 
 matrix components. 
 
 10.4.1 Specificity will be determined using retention time, UV/VIS spectral analysis,
 chromatographic resolution, or a combination thereof. 
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 Analytical Method Validation and Verification D-103 3 (age deer lo 
 
 10.4.1.1 Identity by retention time will be assessed by comparing the retention
 time of a reference standard to that of the sample. A tolerance of +/- 0.3
 
 minutes is generally acceptable. 
 
 10.4.1.2 Peak purity by spectral analysis will be performed by comparing the
 analyte peak spectra against that of a reference standard across a set
 
 wavelength. A spectral match of > 900 is required for Specificity.
 
 10.4.1.3 The USP Resolution between the target analyte and any adjacent peak(s)
 should be characterized. For Drug Products, a minimum resolution of
 
 1.2 is required for Specificity. For dietary supplements, cosmetics, and
 
 functional foods, a minimum resolution of 1.0 is acceptable.
 10.4.1.4 For Drug Products, forced degradation studies are required to ensure a
 
 stability indicating method. Conditions generally include exposure to
 
 acid, base, oxidation, light, and/or heat. In general, conditions should be
 adjusted to obtain 5% - 20% degradation. In some cases (e.g. light or
 
 heat stable analytes), this may not be attainable for all conditions. The
 above requirements for Identity by Retention Time, Peak Purity, and
 
 USP Resolution should be realized in the stressed samples.
 
 10.5 Detection Limit is the lowest amount of analyte in a sample which can be detected but
 not necessarily quantitated as an exact value. 
 
 10.5.1 It is almost never necessary to determine the actual DL or QL. Rather the limit is
 
 shown to be sufficiently low by the analysis of a reference standard or sample
 with concentration of analyte at the limit or specification level. For procedures
 
 that exhibit instrument noise, the signal/noise ratio (S/N) is calculated using the
 
 equation below. DL is defined as the concentration that results in a S/N of 3.
 
 S/N ratio = 2H/h 
 Where H is the height of the peak measured from the peak apex to a
 
 baseline extrapolated over a distance > 5 times the peak width at its half-
 height, and h is the differenece between the largest and smallest noise
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 Analytical Method Validation and Verification D-103 §i<. | eae ole 
 
 values observed over a distance > 5 times the width of the peak at half-
 height and, if possible, situated equally around the peak of interest.
 
 Figure 1: Evaluation of DL/QL 
 
 10.5.2 Perform six replicate injections of a reference standard or sample solution
 
 prepared at the DL level. The S/N is > 3 for all injections. 
 
 10.6 Quantitation Limit is the lowest amount of analyte in a sample which can be
 quantitatively determined with suitable precision and accuracy. 
 
 10.6.1 QL is defined as the concentration that results in a S/N of 10.
 
 10.6.2 Perform six replicate injections of a reference standard or sample solution
 
 prepared at the QL level. The S/N is = 10 for all injections.
 
 10.7. Linearity is the ability, within a given range, of an analytical procedure to obtain
 measurement results which are directly, or by a well-defined mathematical
 
 transformation, proportional to the concentration of analyte in the sample.
 
 10.7.1 Linearity requires at least five concentrations spanning the characterized linear
 range of the assay. The requirement is that R’ > 0.99 unless scientific justification
 
 is given. 
 
 10.8 Range is the interval between the upper and lower concentration of analyte for which it
 has been demonstrated that the procedure has a suitable level of precision, accuracy, and
 
 linearity. Range is evaluated concurrently with Accuracy (Section 10.2) or Linearity
 
 (Section 10.7). 
 10.9 Robustness is a measure of the capacity of an analytical procedure to remain unaffected
 
 by small, but deliberate variations in method parameters and provides an indication of its
 
 
 

[SOP 

 Standard Operating Procedure SOP No | Rev 
 Analytical Method Validation and Verification D-103 g | Sage tot 16 
 
 reliability during normal usage. 
 10.9.1 Robustness is characterized during the method development stage. Robustness
 
 is typically not performed for methods that have been previously validated at
 
 outside laboratories. Acceptance criteria are generally not applied to
 Robustness, but evaluation helps to identify critical method parameters. The
 
 following parameters should be characterized as applicable for Robustness.
 
 Additional robustness parameters not listed here may be considered depending
 on the nature of the analytical method. 
 
 10.9.1.1 Flow Rate 
 
 10.9.1.2 Column Temperature 
 
 10.9.1.3 Injection Volume 
 
 10.9.1.4 Mobile Phase Composition 
 
 10.9.1.5 Compound Stability 
 
 10.9.1.6 Sample Preparation 
 10.10 System Suitability 
 
 10.10.1 Criteria for system suitability can include, but are not limited to, retention time
 
 matching, spectral matching, %RSD of replicate injections, peak resolution,
 peak symmetry, and column efficiency (theoretical plates). The chosen system
 
 suitability criteria should be incorporated into the respective SOP.
 
 10.10.2 For method validations, acceptance criteria for system suitability should be
 chosen based on the Accuracy, Precision, and/or Robustness results to ensure
 
 that, if system suitability is met, the analytical procedure will perform as
 
 intended. 
 
 10.10.3 For method verifications, the acceptance criteria for system suitability listed in
 the compendial or official method should be used without alteration.
 
 10.11 Changes to Validated Methods for use in ISO 17025 accredited tests:
 
 10.11.1 When changes are made to validated methods, the influence of such changes
 are determined and where it is determined that they affected the original
 
 
 

[SOP 

 Standard Operating Procedure SOP No Rev 
 Page 15 of 16 
 D-103 
 Analytical Method Validation and Verification 
 validation, a new method validation will be performed. 
 
 11.0 Facilities and Environmental Conditions 
 
 11.1. The laboratory where testing activities will be conducted will be such that the energy
 sources, lighting, and environmental conditions will facilitate the correct performance of
 
 the tests. 
 
 11.2 The technical requirements for the accommodation and environmental conditions that
 can affect the results of the tests will be documented in the associated test methods.
 
 11.3 Environmental conditions requiring control, including storage conditions, will be
 
 monitored by calibrated equipment. 
 
 12.0 Records 
 
 12.1. Method Verification and Validation records including the validation procedure used, the
 specifications of the requirements, determination of the performance characteristics of
 
 the method, results obtained and a statement on the validity of the method, detailing its
 
 fitness for the intended use will be maintained per SOP C-502 Record Storage, Retention,
 and Destruction. 
 
 
 

[SOP 

 Standard Operating Procedure SOP No Rev 
 8 Page 16 of 16 
 D-103 
 Analytical Method Validation and Verification 
 14.0 Revision History 

| Rev | Date | Description of Changes | CCR # | By |
|-----|----------|------------------------|-------|----|
| 1 | 03/19/13 | New procedure. Changed SOP number from F-102 to D-103. Updated SOP format. Expanded current validation practices in line with FDA Guidance 12/01/14 14-0966 B. Johns 2014. Generalized microbial limit testing validation criteria. Updated responsibilities. Add use of validated AOAC methods for use without validation. 06/20/16 Use of validated methods for investigational purposes. Improve 16-0548 B. Johns clarity. 11/17/16 Validation criteria for use in pharmaceuticals and cosmetics 16-1054 B. Johns Update responsibilities. Remove category Ila. Add USP and ICH references. Combine with D-101.0. Add language to allow choice between validation and verification. Remove mass spec from specificity section. Add resolution and forced degradation to 08/17/20 CC-20-0577 S. Sassman specificity section. Change discussion of range to more closely align with USP. Introduce new product verifications. Remove microbial limit testing since this will be addressed in a separate SOP. 11/09/21 Added ISO 17025:2017 requirements. CC-21-0428 J. Maignan Remove new product verifications section and replace with 10/10/22 CC-22-0391 S. Sassman product specific method optimization section. Remove product specific method optimization section since this 12/20/22 will go into its own SOP, add language to ensure clear separation CC-22-0473 S. Sassman of development/validation activities from finished product release. | 13-164 | B. Johns |